• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Check-Cap Ltd.

    9/13/24 5:00:03 PM ET
    $CHEK
    Medical Electronics
    Health Care
    Get the next $CHEK alert in real time by email
    6-K 1 ea0214454-6k_checkcap.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of September, 2024

     

    Commission File No. 001-36848

     

    Check-Cap Ltd.

     

    Check-Cap Building Abba Hushi Avenue

    P.O. Box 1271

    Isfiya, 3009000, Mount Carmel, Israel

    (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES.)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

     

     

     

     

     

    This Form 6-K is being incorporated by reference into Check-Cap Ltd.’s Registration Statements on Form F-3 (File No. 333-211065, 333-225789 and 333-262401) and Form S-8 (File No. 333-203384, 333-226490 and 333-259666) filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    Appointment of Director

     

    On September 5, 2024, the Board of Directors (the “Board”) of Check-Cap Ltd. (the “Company”) appointed Carlos Cheung to serve as a director to hold office until the next annual meeting of shareholders of the Company, or until earlier resignation or removal, to fill an existing vacancy of the Board, as set forth in Article 42 of the Company’s Articles of Association.

     

    Appointment of Interim Chief Financial Officer

     

    On September 8, 2024, the Company appointed David Benaim as the Company’s Interim Chief Financial Officer of the Company (the “Interim CFO”) to replace Iris Even-Tov who departed the Company. In connection with Mr. Benaim’s appointment as Interim CFO, the Company entered into a Services Agreement by and between the Company and Mr. Benaim (the “Services Agreement”). Pursuant to the Services Agreement, the Company will pay Mr. Benaim a monthly fee in an amount equal to US$12,000 in consideration of his services. Additionally, in the event that the Company is required to prepare and Mr. Benaim plays a lead role in preparing an audited annual financial statement of the Company for the 2024 fiscal year, the Company will pay Mr. Benaim an additional US$25,000.

     

    Entry into a Loan Agreement and Amending Letter

     

    On September 8, 2024, the Board approved and ratified a Loan Agreement (the “Loan Agreement”) with Nobul AI Corp. (“Nobul”). Pursuant to the Loan Agreement, the Company agreed to provide Nobul a loan (the “Loan”) in the principal amount of US$6.0 million. The principal outstanding under the Loan will bear interest at 5% per annum, both before and after demand, default, and judgment, and will be payable annually in arrears. The aggregate amount of the Loan and any accrued and unpaid interest thereon will be due and be paid on the date that is 30 days following the date the Business Combination Agreement, dated March 25, 2024, entered into by and between the Company and Nobul (the “BCA”), is terminated or the business combination contemplated thereunder is consummated.

     

    In addition, on September 8, 2024, the Board approved and ratified an amending letter (the “Amending Letter”) with Nobul. The Amending Letter amends the BCA and obligates the Company to deposit US$11.0 million into a designated, segregated and interest-bearing bank account. Funds deposited into this account may be disbursed upon the mutual written agreement of the designated representatives of Nobul and the Company (being their respective board chairs) in order to fund the pursuit of accretive acquisition targets or other growth initiatives of Nobul and for no other purpose. Any funds so disbursed will reduce the Net Cash Target (as defined in the BCA) on a dollar-for-dollar basis. In the event that the BCA is terminated, then, subject to the payment of any termination fees triggered by Section 9.3(c) of the BCA, funds remaining in the segregated account upon termination, together with interest earned thereon, will accrue to and will be for the account and benefit of the Company.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Check-Cap Ltd.
         
    Date: September 13, 2024 By: /s/ David Lontini
        Name:  David Lontini
        Title: Board Chair, Check-Cap Ltd.

     

     

    2

     

     

    Get the next $CHEK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CHEK

    DatePrice TargetRatingAnalyst
    8/9/2021$4.00 → $3.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CHEK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MediPharm Labs Files Proxy Materials, Issues Chair's Letter to Shareholders

      TORONTO, May 13, 2025 /PRNewswire/ - MediPharm Labs Corp. (TSX:LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, has filed its Management Information Circular ("MIC" or the "Circular") and proxy materials (the "Meeting Materials") for its upcoming Annual and Special Meeting of Shareholders, scheduled for June 16, 2025. The Meeting Materials will be sent to shareholders in the coming days, and are available on the SEDAR+ website at www.sedarplus.ca. MediPharm's Board of Directors (the "Board") recommends that shareholders vote through the GREEN proxy or GREEN voting instruction card in support of the Company's nominees for Board of Dir

      5/13/25 7:31:00 AM ET
      $CHEK
      Medical Electronics
      Health Care
    • Apollo Technology Capital Corporation to Nominate Six Highly Qualified Directors to MediPharm Labs' Board of Directors Following Years of Shareholder Value Destruction

      Believes Board Change is Urgently Needed: Under the Current Board and Management, MediPharm Stock Price is Down More Than 99%, Costing Shareholders Nearly $1 Billion MediPharm's Board Cannot be Trusted to Create Shareholder Value or Oversee Management! Company Leadership Lacks Any Credible Strategic Plan and Has Made Numerous Reckless Acquisitions While Rewarding Themselves with Excessive Compensation for Repeated Failures Apollo's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Execute Plan to Restore Value for ALL MediPharm Shareholders Urges MediPharm Shareholders to Vote for Wholesale Change at Annual Meeting Sends Le

      5/9/25 2:08:00 PM ET
      $CHEK
      Medical Electronics
      Health Care
    • Apollo Technology Capital Corporation to Nominate Six Highly Qualified Directors to MediPharm Labs' Board of Directors Following Years of Shareholder Value Destruction

      Believes Board Change is Urgently Needed: Under the Current Board and Management, MediPharm Stock Price is Down More Than 99%, Costing Shareholders Nearly $1 Billion MediPharm's Board Cannot be Trusted to Create Shareholder Value or Oversee Management! Company Leadership Lacks Any Credible Strategic Plan and Has Made Numerous Reckless Acquisitions While Rewarding Themselves with Excessive Compensation for Repeated Failures Apollo's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Execute Plan to Restore Value for ALL MediPharm Shareholders Urges MediPharm Shareholders to Vote for Wholesale Change at Annual Meeting Sends Let

      5/8/25 7:30:00 AM ET
      $CHEK
      Medical Electronics
      Health Care

    $CHEK
    Financials

    Live finance-specific insights

    See more
    • Keystone Dental Group Granted Patent from USPTO for Nexus IOS Solution

      IRVINE, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Osteon Medical, a subsidiary of Keystone Dental Holdings ("Keystone Dental" or the "Company"), today announced the United States Patent and Trademark Office (USPTO) has granted the Company a patent for its innovative Nexus IOS solution. The Nexus iOS Scan Gauge technology allows implant dentists to perform direct full-arch implant scans using an Intraoral Scanner (IOS) with predictable and passive fitting prosthetic outcomes. This technology replaces the traditionally manual impression-taking process through a faster, cost-effective, and accessible workflow. The Nexus iOS Scan Gauge technology is now the only patented elongated body scan

      10/18/23 4:05:00 PM ET
      $CHEK
      Medical Electronics
      Health Care
    • Keystone Dental Holdings and Check-Cap Ltd Enter into Definitive Business Combination Agreement

      Proposed business combination to create a Nasdaq-listed medical device company focused on advancing the commercial execution and market development of Keystone's comprehensive portfolio of implants, arches and other tooth replacement solutions Keystone 2022 revenues exceeded $60 million The combined company will trade on the NASDAQ with the ticker "KSD" Investor conference call and webcast scheduled for 8:30 a.m. ET on Thursday, August 17th IRVINE, Calif. and BURLINGTON, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Keystone Dental Holdings, Inc. ("Keystone Dental") and Check-Cap Ltd. ("Check-Cap" or the "Company") (NASDAQ:CHEK) today announced that they have entered into a definitive Busin

      8/16/23 5:08:47 PM ET
      $CHEK
      Medical Electronics
      Health Care

    $CHEK
    SEC Filings

    See more
    • SEC Form NT 20-F filed by Check-Cap Ltd.

      NT 20-F - Check-Cap Ltd (0001610590) (Filer)

      5/1/25 4:15:02 PM ET
      $CHEK
      Medical Electronics
      Health Care
    • SEC Form 6-K filed by Check-Cap Ltd.

      6-K - Check-Cap Ltd (0001610590) (Filer)

      4/15/25 4:15:15 PM ET
      $CHEK
      Medical Electronics
      Health Care
    • SEC Form 6-K filed by Check-Cap Ltd.

      6-K - Check-Cap Ltd (0001610590) (Filer)

      12/31/24 4:15:09 PM ET
      $CHEK
      Medical Electronics
      Health Care

    $CHEK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Check-Cap Ltd. (Amendment)

      SC 13D/A - Check-Cap Ltd (0001610590) (Subject)

      4/8/24 7:35:32 PM ET
      $CHEK
      Medical Electronics
      Health Care
    • SEC Form SC 13D filed by Check-Cap Ltd.

      SC 13D - Check-Cap Ltd (0001610590) (Subject)

      4/1/24 9:26:38 PM ET
      $CHEK
      Medical Electronics
      Health Care
    • SEC Form SC 13D/A filed by Check-Cap Ltd. (Amendment)

      SC 13D/A - Check-Cap Ltd (0001610590) (Subject)

      12/18/23 6:07:13 AM ET
      $CHEK
      Medical Electronics
      Health Care

    $CHEK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Check-Cap with a new price target

      HC Wainwright & Co. reiterated coverage of Check-Cap with a rating of Buy and set a new price target of $3.00 from $4.00 previously

      8/9/21 6:35:25 AM ET
      $CHEK
      Medical Electronics
      Health Care
    • Check-Cap downgraded by Dawson James with a new price target

      Dawson James downgraded Check-Cap from Buy to Neutral and set a new price target of $2.00

      3/17/21 12:12:30 PM ET
      $CHEK
      Medical Electronics
      Health Care
    • HC Wainwright & Co. reiterated coverage on Check-Cap with a new price target

      HC Wainwright & Co. reiterated coverage of Check-Cap with a rating of Buy and set a new price target of $4.00 from $1.50 previously

      3/16/21 6:31:50 AM ET
      $CHEK
      Medical Electronics
      Health Care

    $CHEK
    Leadership Updates

    Live Leadership Updates

    See more
    • Symetryx Today Issues Open Letter to Shareholders In Regard to the Upcoming Annual General Meeting

      Recommends Fellow Shareholders Vote AGAINST Keystone Transaction & the Check-Cap Board Nominees - Further Recommends a Vote FOR the Symetryx Slate of Director Candidates Cites Unrealistic and Aggressive Valuation of Keystone Used to Justify the Merger and Troubling Cash Burn by Check-Cap Board & Management TORONTO, Nov. 28, 2023 /PRNewswire/ - Symetryx, a holder of 5.6% of Check-Cap Ltd. (NASDAQ:CHEK) shares, today issued the following open letter to shareholders. In the letter Symetryx cites, among other items, its serious concerns and reason for voting AGAINST the proposed transaction with Keystone Dental.  Symetryx discusses its concerns around the actions of the Board in its evaluation

      11/28/23 11:56:00 AM ET
      $CHEK
      Medical Electronics
      Health Care
    • Check-Cap Appoints Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs

      ISFIYA, Israel, Sept. 1, 2021 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ:CHEK), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced the appointment of Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs. Dr. Brenner-Lavie will be responsible for leading the Company's overall clinical strategy and implementation as well as driving the Company's clinical direction, including innovation. "Dr. Brenner-Lavie has a proven track record of clinical strategy dev

      9/1/21 8:30:00 AM ET
      $CHEK
      Medical Electronics
      Health Care